Kadia Siddhartha 4

What Happened
Kadia Siddhartha, President and CEO of MESA Laboratories, was granted 34,807 restricted stock units (RSUs) on 2026-04-14. The grant is reported as a derivative award (Form 4 code A) at $0.00 per unit; each RSU represents the right to receive one share of MESA common stock upon vesting. This is a compensation award rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-04-14; reported on Form 4 filed 2026-04-24 (late filing — reported 10 days after the transaction).
• Instrument and amount: 34,807 RSUs granted, $0.00 reported price (derivative award).
• Vesting: RSUs vest one‑third (1/3) on each anniversary (per footnote).
• Shares owned after transaction: Not specified in this filing.
• Footnotes: F1—each RSU converts to one share upon vesting; F2—vesting schedule 1/3 each anniversary; F3—Not Applicable.
• Timeliness: Filing appears late (transaction on 4/14, filed 4/24); late Form 4s may indicate administrative delay but should be noted by investors.

Context
RSU grants are common executive compensation to align management with shareholder value over time. Because these RSUs vest over multiple anniversaries, they do not represent immediately tradable shares and are not the same signal as an insider purchase or sale. Investors should view this as a compensation-related grant rather than a direct market bet by the CEO.